Back to top
more

Masimo (MASI)

(Real Time Quote from BATS)

$113.34 USD

113.34
12,573

-0.93 (-0.81%)

Updated Sep 6, 2024 10:12 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

IRadimed (IRMD) Q3 Earnings and Revenues Top Estimates

iRadimed (IRMD) delivered earnings and revenue surprises of 20.83% and 1.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ConforMIS (CFMS) Reports Q3 Loss, Misses Revenue Estimates

ConforMIS (CFMS) delivered earnings and revenue surprises of -14.29% and 0.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Can Cigna's (CI) Q3 Earnings Beat on Evernorth Performance?

The third-quarter results of Cigna (CI) are likely to reflect a rise in total medical customers.

Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?

Cardinal Health's (CAH) first-quarter fiscal 2023 results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.

Why Masimo (MASI) is Poised to Beat Earnings Estimates Again

Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

The Zacks Analyst Blog Highlights Nevro, Masimo, Abiomed and Glaukos

Nevro, Masimo, Abiomed and Glaukos are part of the Zacks top Analyst Blog.

Indrajit Bandyopadhyay headshot

4 MedTech Stocks Set to Outpace Q3 Earnings Estimates

Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.

Edwards Lifesciences (EW) to Report Q3 Results: Wall Street Expects Earnings Growth

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Masimo (MASI) Q3 Earnings Expected to Decline

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Masimo's (MASI) Latest Watch to Improve Patient Outcomes

Masimo's (MASI) full-market consumer release of the Masimo W1 and other related launches is likely to significantly improve RPM.

Masimo's (MASI) Q2 Earnings Surpass Estimates, Margins Down

Masimo's (MASI) robust product shipments and strength in its healthcare business drive its Q2 sales.

Masimo (MASI) Q2 Earnings and Revenues Top Estimates

Masimo (MASI) delivered earnings and revenue surprises of 13.45% and 4.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

RxSight, Inc. (RXST) Reports Q2 Loss, Tops Revenue Estimates

RxSight, Inc. (RXST) delivered earnings and revenue surprises of 26.47% and 0.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

LivaNova (LIVN) Q2 Earnings and Revenues Surpass Estimates

LivaNova (LIVN) delivered earnings and revenue surprises of 3.92% and 2.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

IRadimed (IRMD) Beats Q2 Earnings and Revenue Estimates

iRadimed (IRMD) delivered earnings and revenue surprises of 12.50% and 0.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Fresenius Medical (FMS) Stock Now

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Study Favors Masimo's (MASI) SafetyNet for Better Patient Outcome

Masimo's (MASI) SafetyNet is expected to reduce the duration of hospitalization for COVID-19 patients and create more bed capacity in hospitals.

Here's Why You Should Retain McKesson (MCK) Stock Right Now

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Here's Why You Should Buy ShockWave Medical (SWAV) Stock

ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies.

3 Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio

Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.

NuVasive (NUVA) to Expand in APAC With New Experience Center

NuVasive's (NUVA) Singapore Experience Center will complement the flagship Experience Centers in San Diego and the New York metropolitan area.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

Investors are optimistic about STERIS (STE) owing to its robust segmental results and the ongoing Cantel Medical integration.

BD's (BDX) New Combination Test to Boost Patient Outcome

BD's (BDX) latest combination test is expected to speed up the detection of the infection-causing viruses, thereby accelerating the implementation of the appropriate treatment plan.

Intuitive (ISRG) New Lung Biopsy Imaging Technology Gets FDA Nod

The FDA clears the integration of mobile cone-beam CT imaging technology with Intuitive's (ISRG) Ion Endoluminal System, enhancing a physician's ability to provide minimally invasive lung biopsy.

Catalent (CTLT) Expands Packaging Capabilities at Japan Facility

Catalent's (CTLT) latest capability expansion is expected to boost its business in this key hub in its Asia-Pacific Clinical Supply Services network.